Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Miller

Showing results (81-90 of 123) with videos related to

Pageof 13
Sort By:
Journal of the American College of Surgeons|February 7, 2018
Short-Term Preoperative Weight Loss and Postoperative Outcomes in Bariatric SurgeryDeborah A Hutcheon, Allyson L Hale, Joseph A Ewing, et al.
Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
The International Journal on Drug Policy|June 11, 2026
Mobile but still tied down: Challenges to scaling mobile methadone through a regulatory thicketNoa Krawczyk, Megan Miller, David Frank, et al.
Addiction (Abingdon, England)|January 17, 2025
Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communitiesNoa Krawczyk, Megan Miller, Emma Yuanqi Gu, et al.
Vascular Medicine (London, England)|August 22, 2017
Regulation of endothelial hemoglobin alpha expression by Kruppel-like factorsPanjamaporn Sangwung, Guangjin Zhou, Yuan Lu, et al.
The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.
Addiction Science & Clinical Practice|June 25, 2026
"How are we going to be able to pull that off?": staff perspectives on the early implementation of mobile medication units in New York StateMegan Miller, Minna Song, Alexandra Bessler, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.
The Journal of Investigative Dermatology|June 27, 2024
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2Andrew Blauvelt, Kenneth B Gordon, Richard G Langley, et al.
Pageof 13

Showing results (81-90 of 123) with videos related to

Sort By:
Pageof 13
Journal of the American College of Surgeons|February 7, 2018
Short-Term Preoperative Weight Loss and Postoperative Outcomes in Bariatric SurgeryDeborah A Hutcheon, Allyson L Hale, Joseph A Ewing, et al.
Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
The International Journal on Drug Policy|June 11, 2026
Mobile but still tied down: Challenges to scaling mobile methadone through a regulatory thicketNoa Krawczyk, Megan Miller, David Frank, et al.
Addiction (Abingdon, England)|January 17, 2025
Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communitiesNoa Krawczyk, Megan Miller, Emma Yuanqi Gu, et al.
Vascular Medicine (London, England)|August 22, 2017
Regulation of endothelial hemoglobin alpha expression by Kruppel-like factorsPanjamaporn Sangwung, Guangjin Zhou, Yuan Lu, et al.
The British Journal of Dermatology|April 6, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposureMark G Lebwohl, Joseph F Merola, Katelyn Rowland, et al.
Addiction Science & Clinical Practice|June 25, 2026
"How are we going to be able to pull that off?": staff perspectives on the early implementation of mobile medication units in New York StateMegan Miller, Minna Song, Alexandra Bessler, et al.
The Journal of Dermatological Treatment|July 15, 2025
The hf-PGA is a valid and reliable measure of hand/foot psoriasis severity in adults: results from a phase 2b clinical trialRobert Bissonnette, Ronald Vender, Andreas Pinter, et al.
Journal of Drugs in Dermatology : JDD|February 6, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc AnalysesKenneth B Gordon, Joseph F Merola, Peter Foley, et al.
The Journal of Investigative Dermatology|June 27, 2024
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2Andrew Blauvelt, Kenneth B Gordon, Richard G Langley, et al.
Pageof 13